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Abstract: We describe a case of a 25 year old female from Lithuania who presented with a productive cough. Chest ra-
diograph demonstrated an infiltrate in the left upper lobe and a cavitating lesion in the right middle lobe. Sensitivity test-
ing of her sputum led to a diagnosis of extensively drug-resistant tuberculosis (XDR-TB). This is the first case in Ireland 
and highlights the need for physicians to be aware of the possibility of XDR-TB. Moreover it underlines the need for im-
provement in service provision in terms of a TB reference laboratory and TB clinics. 
  A 25-year-old female, non-smoker, originally from 
Lithuania who had been living in Ireland for 2 years pre-
sented with a two month history of cough productive of 
brown sputum. She had no weight loss, night sweats, or 
dyspnoea. The full blood count was normal, HIV test nega-
tive and chest radiograph demonstrated an area of infiltration 
in the left upper lobe and a cavitating lesion of the right mid-
dle lobe (Fig. 1). Diagnostic investigations confirmed acid 
fast bacillus in the sputum and she was commenced on anti-
tuberculous treatment. Nine days later TB culture demon-
strated resistance to all first line agents. She was commenced 
on oral moxifloxacin, prothionimide, PAS, cycloserine and 
intramuscular capreomycin. She was discharged home on 
Directly Observed Therapy (DOT) in close conjunction with 
our Public Health colleagues. 
 
Fig. (1). Chest radiograph demonstrating an area of infiltration in 
the left upper lobe and a cavitating lesion in the right middle lobe. 
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  Five weeks following initial diagnosis, the extensively 
drug-resistant tuberculosis (XDR-TB) profile (Table 1), was 
reported and demonstrated sensitivity to capreomycin, clo-
fazimine, prothionimide and cycloserine. Resistance was 
noted to amikacin, streptomycin, isoniazid, rifampicin, eth-
ambutol, pyrazinamide, ciprofloxin, clarithromycin, rifabutin 
and PAS. Second line susceptibility were performed in ra-
diometric Bactec™ in 2 reference laboratories. In view of  
 
Table 1.  Sensitivities of the Isolated Mycobacterium Tuberculosis 
 
Antibiotic Sensitivity/Resistance 
Isoniazid R 
Rifampicin R 
Ethambutol R 
Pyrazinamide R 
Streptomycin R 
Amikacin R 
Ciprofloxacin R 
Clarithromycin R 
Rifabutin R 
PAS R 
Capreomycin S 
Prothionimide S 
Clofazimine S 
Cycloserine S 
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the resistance, treatment was continued on the 4 drug regi-
men: moxifloaxin, cycloserine, prothionimide and capreo-
mycin. She became smear negative after 2 months of ther-
apy. After eight months she developed tinnitus and the ca-
preomycin was stopped, audiogram was normal. She re-
ceived DOT therapy for a total of 20 months. Chest radio-
graph following 20 months of therapy demonstrated no evi-
dence of active disease or evidence of old fibrocalcific dis-
ease. 
DISCUSSION 
  XDR-TB was first described as an entity in March 2006, 
in
 a report jointly published by the US Centers for Disease 
Control
 and Prevention (CDC) and WHO [1]. At this point, it 
was described as a disease caused
 by strains of Mycobacte-
rium tuberculosis that were resistant
  not only to isoniazid 
and rifampicin (i.e. MDR-TB) but also
 to at least three of the 
six classes of second-line anti-TB
  drugs (aminoglycosides, 
polypeptides, fluoroquinolones, thioamides,
 cycloserine and 
para-aminosalycilic acid). XDR-TB was redefined at a meet-
ing of the
 WHO XDR-TB Task Force, in October 2006, in 
Geneva, such that it is now defined as: resistance to
 at least 
rifampicin and isoniazid (which is the definition of
  MDR-
TB), in addition to any fluoroquinolone, and to at least
 one of 
the three following injectable drugs used in anti-TB
  treat-
ment: capreomycin, kanamycin and amikacin [2]. 
  Because of its recent description, there is a paucity of 
published data on the prevalence of XDR-TB. In the USA, 
4% of the MDR-TB strains isolated between 1993 and
 2004 
were XDR-TB. In Europe,
 representative data are available 
from Latvia [3] where 19% of
 the MDR strains isolated from 
2000-2002 were XDR and Norway, where an outbreak of 23
 
cases (15 of them being XDR) has been ongoing for >10 yrs 
[4]
. In Asia, data are available from South Korea [5], where 
15% of the MDR-TB strains isolated in 2004 were XDR,
 and 
also Iran [6] where 12 (10.9%) of 113 MDR-TB strains iso-
lated
 were XDR. However it is the emergence of XDR-TB in 
South Africa that is of particular concern since XDR-TB 
transmission to HIV co-infected patients is associated with a 
high mortality rate there [7]. Furthermore, it is estimated that 
there are >63,000
 MDR-TB cases in the countries of
 the for-
mer Soviet Union [8]. 
  The largest European study on XDR-TB has recently 
been published and it highlights two important points firstly 
XDR-TB cases are frequently not identified in clinical prac-
tice, and of even greater concern that XDR-TB cases
 have a 
clinical outcome worse than MDR-TB. This indicates that 
the XDR diagnosis has important treatment and prognostic 
values [9]. Attention has also focused on coexistence of HIV 
and XDR-TB. Of 536 TB patients in the small town of 
Tugela Ferry in KwaZulu-Natal, 221 were found to have 
multidrug resistance and of these, 53 were diagnosed with 
XDR-TB. Fifty-two of these patients died, most within 25 
days. Of the 53 patients, 44 had been tested for HIV and all 
44 were found to be HIV-positive. The patients were receiv-
ing antiretrovirals and responding well to HIV-related treat-
ment, but they died of XDR-TB [10]. 
  Correct and complete treatment of MDR-TB and XDR-TB 
is vital both for the individual patient and the community.   
 
There are no published guidelines on the management of 
XDR-TB. Guidelines on the management of MDR-TB suggest 
use of 4-6 drugs [11,12] although the optimal number of drugs 
used in a retreatment regimen for MDR-TB has never been 
studied in a clinical trial. As part of the regimen, a daily in-
jectable medication should be used until at least 6 months of 
negative cultures have been documented and a fluoroqui-
nolone should be used where possible. Additionally DOT, 
aggressive management of adverse effects, rigorous drug sus-
ceptibility testing and adjuvant resective surgery where neces-
sary should be considered. In some cases empiric MDR-TB 
treatment may be required whilst awaiting results of antimi-
crobial-sensitivity. In these cases, it is important to commence 
at least six agents to which the infecting strain is likely to be 
sensitive, avoiding drugs which the patient has received in the 
past and bearing in mind local resistance patterns. 
  The emergence of MDR and XDR-TB in Ireland requires 
us to take several measures: These include offering TB dis-
ease and Latent TB infection (LTBI) screening, followed by 
treatment when appropriate, to all new entrants from high 
TB endemic countries. Additionally, we should improve our 
laboratory capacity for susceptibility testing of second line 
drugs. We can also improve our Public Health service by 
ensuring more rapid contact tracing and medication compli-
ance, though easy access to DOT. There is now a responsi-
bility on medical and scientific TB personnel to develop 
methods to rapidly diagnose smear-negative
  TB cases, to 
evaluate new markers of TB infection and disease, to de-
velop new drugs for the treatment of TB and to develop in-
ternational standards and guidelines for the management of 
drug resistant TB. 
  This case highlights an emerging health problem in 
Europe and underlines the necessity for physicians to be 
aware of MDR and XDR-TB in patients and most particu-
larly in patients presenting from areas of high prevalence.  
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